This study found a HER2-positivity gain in 20.7% of cases, with some evidence of longer median OS in these patients, although at a not fully statistically significant extent [ 55 ].
← all excerpts
Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease.
1
—
—